Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E19.95 EPS (ttm)3.84 Insider Own0.07% Shs Outstand2.55B Perf Week-7.02%
Market Cap195.28B Forward P/E12.17 EPS next Y6.29 Insider Trans-5.64% Shs Float2.54B Perf Month-12.24%
Income9.91B PEG2.37 EPS next Q1.35 Inst Own78.00% Short Float1.00% Perf Quarter-12.34%
Sales46.84B P/S4.17 EPS this Y33.00% Inst Trans0.27% Short Ratio2.62 Perf Half Y-11.47%
Book/sh10.49 P/B7.30 EPS next Y9.96% ROA11.30% Target Price97.94 Perf Year-5.82%
Cash/sh3.14 P/C24.35 EPS next 5Y8.43% ROE34.40% 52W Range72.23 - 92.64 Perf YTD-15.82%
Dividend2.44 P/FCF81.77 EPS past 5Y10.60% ROI11.70% 52W High-17.36% Beta0.59
Dividend %3.19% Quick Ratio1.00 Sales past 5Y-0.80% Gross Margin70.20% 52W Low5.99% ATR1.93
Employees69000 Current Ratio1.30 Sales Q/Q14.90% Oper. Margin25.30% RSI (14)20.00 Volatility3.34% 2.06%
OptionableYes Debt/Eq0.97 EPS Q/Q1.50% Profit Margin20.00% Rel Volume2.85 Prev Close78.08
ShortableYes LT Debt/Eq0.84 EarningsFeb 05 BMO Payout59.20% Avg Volume9.67M Price76.56
Recom1.90 SMA20-8.42% SMA50-12.36% SMA200-9.68% Volume27,562,507 Change-1.95%
Feb-27-20Initiated Barclays Overweight $93
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Feb-28-20 06:46PM  How the Coronavirus Will Challenge the Health-Care Industry Barrons.com
09:07AM  FDA Reports First Drug Shortage Due to Coronavirus, Far Earlier Than Expected Barrons.com
Feb-27-20 03:04PM  Why coronavirus is a 'shock' to global economy NC State economist weighs in American City Business Journals
06:45AM  Merck to Present at the Cowen Health Care Conference Business Wire
Feb-26-20 12:27PM  Coronavirus fears sparks market swings Yahoo Finance Video
Feb-25-20 04:57PM  Peter Thiels Palantir Wins Role in $823 Million Government Contract Bloomberg
03:20PM  Moderna soars on vaccine progress for coronavirus Yahoo Finance Video
Feb-22-20 01:00PM  Benzinga's Bulls And Bears Of The Week: Merck, Nike, Target And More Benzinga
Feb-21-20 02:36PM  Triad university to dedicate business college in honor of donor, alumni American City Business Journals
10:03AM  Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval Zacks
Feb-20-20 04:51PM  4 Most Popular Healthcare Stocks Among Hedge Funds: Q4 Rankings Insider Monkey
Feb-19-20 09:51AM  Jim Simons: The Investing Guru Bets on These 3 Healthcare Stocks TipRanks
Feb-18-20 07:17PM  Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule Business Wire
Feb-14-20 11:20AM  ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification Business Wire
Feb-13-20 02:25PM  3 Dow Jones Industrial Average Stocks to Sell InvestorPlace
Feb-12-20 05:55PM  Richard Pzena Trims Walmart, Merck Positions GuruFocus.com
02:54PM  Merck Shares Slip In Favor of a Peer, Evercore ISI Says Bloomberg
06:45AM  Mercks KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC) Business Wire
Feb-11-20 03:11PM  Ethics in Stock Picking GuruFocus.com
07:23AM  The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-10-20 05:54AM  This once-faltering cancer startup just raised $117M. Heres how it plans to spend it. American City Business Journals
Feb-09-20 03:22PM  The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight Benzinga
09:38AM  Merck & Co., Inc. Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St.
Feb-07-20 04:57PM  An Experts Advice for Cutting Your Tax Bill Barrons.com
03:07PM  How Big a Hit? Health-Care Companies Try to Gauge the Costs of Coronavirus. Barrons.com
12:32PM  What to expect from new Merck spinoff, according to the CEO American City Business Journals
11:15AM  Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales Zacks
10:24AM  Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split Zacks
Feb-06-20 05:36PM  J&J Brand Most Valuable Among Pharmaceutical Companies GuruFocus.com
03:48PM  Merck Will No Longer Be Easy to Own on Keytruda Dominance Bloomberg
03:45PM  Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates Zacks
11:45AM  Why Merck (MRK) is a Great Dividend Stock Right Now Zacks
09:49AM  US Indexes Close Higher With Impeachment Acquittal GuruFocus.com
06:59AM  Bristol-Myers earnings rise due to Celgene deal Reuters
05:12AM  Merck Sharp & Dohme Corp. -- Moody's affirms Merck's A1/Prime-1 ratings; stable outlook Moody's
05:01AM  Why Merck Is Spinning Off 3 Divisions, and Two More Numbers to Know Barrons.com
02:01AM  PRESS DIGEST -Wall Street Journal - Feb 6 Reuters
01:17AM  Edited Transcript of MRK earnings conference call or presentation 5-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-05-20 06:02PM  Merck Shares Drop After Spinoff Announced GuruFocus.com
04:22PM  US STOCKS-S&P 500, Nasdaq mint record highs after strong U.S. data, waning virus fears Reuters
03:02PM  US STOCKS-Wall St gains after strong US data, waning virus fears; Tesla limits Nasdaq's rise Reuters
12:07PM  Strong Private Sector Payrolls in January Zacks
11:42AM  Merck & Co., Inc. -- Moody's affirms Merck's A1/Prime-1 ratings; stable outlook Moody's
10:42AM  ADP Posts Blowout +291K New Jobs for January Zacks
09:47AM  Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off Zacks
09:46AM  Dow tries for a 3rd day of gains amid upbeat data, hope of coronavirus treatments MarketWatch
09:36AM  Merck Tops Q4 Profit Forecast, Plans Womens' Health, Biosimilars Spinoff TheStreet.com
09:26AM  Merck to streamline business, separate into two companies American City Business Journals
09:22AM  Merck Is Spinning Off 3 Divisions to Focus on Key Growth Drivers, CEO Ken Frazier Said Barrons.com
09:15AM  Stocks - GM Rises in Premarket; Merck Falls on Spin-Off News Investing.com
09:11AM  Merck's stock is the only Dow member losing ground, after earnings and spinoff news MarketWatch
08:42AM  Ford Motor Stock, Snap Are Sliding, but Hope About Coronavirus Is Lifting the Dow Barrons.com
07:40AM  Merck to spin off assets in bid to streamline its business Financial Times
07:05AM  Merck announces spinoffs, reports profit beat but sales miss; stock falls MarketWatch
06:53AM  Merck to spin-off women's health, biosimilar businesses Reuters
06:47AM  Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results Business Wire
06:45AM  Merck to Focus on Key Growth Pillars Through Spinoff of Womens Health, Trusted Legacy Brands and Biosimilars Products into New Company ("NewCo") Business Wire
06:00AM  Merck & Co., Inc. to Host Earnings Call ACCESSWIRE
01:49AM  Merck&Co Earnings Beat, Revenue Misses In Q4 Investing.com
Feb-04-20 04:15PM  Merck's Keytruda: How Long Can It Fend Off Cancer-Treatment Rivals? Investor's Business Daily
12:39PM  Day Ahead: Top 3 Things to Watch for Feb. 5 Investing.com
12:08PM  Merck's Keytruda: How Long Can It Fend Off Cancer-Treatment Rivals? Investor's Business Daily
10:32AM  Should You Buy Merck (MRK) Ahead of Earnings? Zacks
10:24AM  Merck's Recarbrio Gets FDA Priority Review for New Indication Zacks
10:13AM  Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q4 Earnings? Zacks
09:49AM  US Indexes End Higher Monday to Start February GuruFocus.com
08:03AM  AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards? Zacks
07:30AM  Merck Reports Earnings Tomorrow. Heres What to Expect. Barrons.com
Feb-03-20 05:42PM  Bristol-Myers' Opdivo-Yervoy NSCLC Application in EU Withdrawn Zacks
02:27PM  Are Investors Undervaluing Merck & Co., Inc. (NYSE:MRK) By 33%? Simply Wall St.
01:06PM  Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards? Zacks
12:01PM  Nike, Walt Disney share gains lead Dow's 183-point jump MarketWatch
11:00AM  Dow up 300 points on gains for Nike, Merck stocks MarketWatch
10:18AM  Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings Zacks
10:06AM  Will Eylea & Dupixent Drive Regeneron's (REGN) Q4 Earnings? Zacks
09:45AM  Nike, Merck share gains contribute to Dow's 225-point climb MarketWatch
09:06AM  The Extreme Risks of Trading Your Own Retirement Assets - February 03, 2020 Zacks
06:54AM  Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing? Zacks
06:45AM  FDA Accepts For Review Supplemental New Drug Application (sNDA) for RECARBRIO (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Business Wire
Feb-01-20 10:56AM  Bernie Sanders surge in the polls could hit the S&P 500 with Iowa Caucus vote due this week, analysts warn MarketWatch
10:53AM  Coronavirus update: WHO says prepare for local coronavirus outbreaks in other countries MarketWatch
10:02AM  Disney and Alphabet could put an end to the earnings recession MarketWatch
Jan-31-20 04:05PM  Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors Business Wire
10:52AM  Some Drugmakers Are Racing to Develop a Coronavirus Vaccine. Why Big Pharma Isnt Rushing In. Barrons.com
10:32AM  Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative Zacks
09:17AM  Will Strong HIV Sales Drive Gilead's (GILD) Q4 Earnings? Zacks
09:08AM  Old Dominion (ODFL) to Report Q4 Earnings: What's in Store? Zacks
09:05AM  Want To Retire Early? Learn the Intelligent Investing Secret - January 31, 2020 Zacks
Jan-28-20 05:50PM  Kahn Brothers' Biggest 4th-Quarter Buys GuruFocus.com
02:40PM  Kahn Brothers Trims Holdings of Merck, Citigroup GuruFocus.com
02:36PM  Merck's Dificid Gets FDA Approval in Pediatric Indication Zacks
01:21PM  Merck Announces Second-Quarter 2020 Dividend Business Wire
10:31AM  Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down Zacks
09:49AM  Pfizer Stock Could Test 2019 Low Investopedia
07:41AM  The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power Zacks
06:30AM  BriaCells Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston GlobeNewswire
02:00AM  Lung Cancer Study Shows Barriers in Patient Access to Care in Europe Business Wire
Jan-27-20 05:45PM  Merck (MRK) Gains As Market Dips: What You Should Know Zacks
03:33PM  Top Stock Analyst Reports for Merck, Broadcom & Sanofi Zacks
08:16AM  Lilly (LLY) to Report Q4 Earnings: What's in the Cards? Zacks
Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It also offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fish. Further, it offers companion animal products; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; horse fertility management products; dog, cat, and horse vaccines; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Intec Pharma Ltd.; Nerviano Medical Sciences; Healthy Interactions, Inc.; Oncologie, Inc.; Themis Bioscience; I-MAB Biopharma Co., Ltd.; 4D pharma plc; Promega Corporation; Seattle Genetics, Inc.; Astellas Pharma, Inc.; Seven and Eight BioPharmaceuticals Inc.; InxMed (Shanghai) Co., Ltd.; genOway; and Atreca, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJan 13Option Exercise0.0082,5480139,111Jan 15 05:15 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJan 13Sale89.34102,0739,118,86537,038Jan 15 05:15 PM
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise0.002,28706,196Nov 01 05:07 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise0.004,57404,574Nov 01 05:07 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise0.002,287073,032Nov 01 05:06 PM
Scholefield James HEVP,Chief Info&Digital OfficerOct 30Option Exercise0.0011,436011,436Nov 01 05:04 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Option Exercise0.006,427077,951Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Sale85.096,427546,85071,524Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Option Exercise0.0031,6990103,223Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Sale85.0131,6992,694,78971,524Aug 12 05:13 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Option Exercise0.00216,7180354,378Jun 27 05:05 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Sale85.43216,71818,514,032137,660Jun 27 05:05 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 10Option Exercise0.003,292022,412May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 10Option Exercise0.004,389071,993May 13 05:05 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 10Option Exercise0.001,50903,317May 13 05:05 PM
Nally MichaelEVP, Chief Marketing OfficerMay 10Option Exercise0.001,81104,376May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Option Exercise39.2925,000982,25092,604May 09 06:11 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Sale77.7325,0001,943,18367,604May 09 06:11 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise0.005,77205,772May 07 07:42 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise0.001,29802,935May 07 07:40 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise0.001,904068,542May 07 07:37 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.001,212019,717May 07 08:32 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise0.0069202,046May 07 08:32 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Option Exercise39.2935,0001,375,150106,064May 07 08:33 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Sale80.0035,0002,800,00071,064May 07 08:33 PM
Merck & Co., Inc.10% OwnerApr 08Buy16.004,121,68365,946,92812,955,016Apr 09 06:27 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Option Exercise58.22192,57211,211,542330,232Mar 27 05:45 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Sale82.38192,57215,863,119137,660Mar 27 05:45 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Option Exercise39.29192,7367,572,597990,451Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Sale82.05192,73615,813,372797,715Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Option Exercise39.2918,725735,705816,440Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Sale82.0018,7251,535,454797,715Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Option Exercise39.296,961273,498804,676Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Sale82.006,961570,809797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Option Exercise39.2913,144516,428810,859Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Sale82.0113,1441,077,875797,715Mar 06 06:13 PM